revenu ep ahead estim full year ep guidanc rais sale
ep estim consensu ep
guidanc rais prior larg due expect lower
non-oper expens lower tax rate last publish estim
review
sale estim consensu product
beat estim includ taltz alimta olumi cymbalta cyramza
jardianc basaglar verzenio tradjenta trulic combin
forecast product forecast includ ciali humalog zyprexa
strattera combin light sale guidanc reiter
last publish revenu estim
gpm estim
estim sg forecast net non-
oper expens estim pre-tax margin
estim tax rate estim one-tim
discret benefit ad ep share count estim
full year non-gaap guidanc updat includ sg vs prior
estim net non-op expens zero vs prior expens
expens estim due gain secur tax rate
vs prior estim remaind guidanc intact
verzenio full ph ii monarch data mbc w/herceptin posit top-lin juli
taltz data vs tremfya psoriasi approv radiograph axspa lasmiditan
approv acut migrain treatment ph ii data /file ret fusion cancer
complet list event shown follow page
pleas see page report import disclosur
cowen compani
good mm cowen
cowen compani www lilli com
cowen compani
cowen compani
cowen compani
cowen compani
time frameev chf exercis abil ret inhibitor phase ii data libretto ret fusion cancersmirikizumabiniti phase crohn sfull phase data atop dermat posit top-lin feb data atop dermat three breez trial pegilodecakinphas top-lin data pancreat cancertaltzphas iv top-lin data ixora-r vs tremfya psoriasisful phase data nr axspa posit top-lin apr phase obes phase ii nashverzenio full ph ii monarch data herceptin bc posiitv top-lin juli approv afp-high reach posit chmp june intranas glucagon eu approvaljardianceu file use insulin adjunctlasmiditanu approv acut migrain ret inhibitor regulatori file nsclc thyroid cancertaltzu approv radiograph axial spondyloarthritiseu/jp file radioigraph axial spondyloarthritiscorporatealimta patentgerman/japan appeal rule late cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
